Oncology

CancerNetwork® spoke with Prithviraj Bose, MD at the Society of Hematologic Oncology 2025 Annual Meeting following a presentation he delivered titled...

The phase 1b/2 KOMET-001 trial (NCT04067336) demonstrated that single-agent ziftomenib, a menin inhibitor, achieved responses in patients with relapse...

The combination of ateganosine (THIO) plus cemiplimab (Libtayo) exhibited durable activity as a third-line treatment in adult patients with advanced n...

Breast cancer is the most commonly diagnosed cancer worldwide, with one in five cases exhibiting the overexpression of the Human Epidermal Growth Fact...

Recent advancements have brought encouraging news for patients with nccRCC, a subtype historically challenging to treat. Unlike clear cell RCC, non–cl...

At the Society of Hematologic Oncology 2025 Annual Meeting, CancerNetwork® spoke with Prithviraj Bose, MD, about the intricacies of myelofibrosis ther...

Treating nccRCC after progression on first-line therapy remains a significant challenge. This group of cancers is highly heterogeneous with different...

For patients with myelofibrosis, ruxolitinib (Jakafi) has been a prominent therapy for over a decade, despite its variability in eliciting responses i...

This segment introduces a Cancer Network Between the Lines Journal Club discussion focused on the KEYNOTE-B61 study examining pembrolizumab plus lenva...

Non–clear cell RCC represents a significant clinical challenge, comprising 25% to 30% of all RCC cases while clear cell RCC accounts for 70% to 75%. T...